177Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.

Saved in:
Bibliographic Details
Title: 177Lu-PSMA SPECT Quantitation at 6 Weeks (dose 2) Predicts Short Progression Free Survival for Patients Undergoing Lu PSMA I&T Therapy.
Authors: John, Nikeith1,2, Pathmanandavel, Sarennya1, Crumbaker, Megan2,3,4, Counter, William1, Bao Ho1, Yam, Andrew O.2,3,4, Wilson, Peter5, Niman, Remy5, Ayers, Maria1, Poole, Aron1, Hickey, Adam1, Agrawal, Shikha1, Perkins, Gary1, Kallinen, Annukka1, Eslick, Enid1, Stockler, Martin R.6, Joshua, Anthony M.2,3,4, Nguyen, Andrew1,2, Emmett, Louise1,2,3 louise.emmett@svha.org.au
Source: Journal of Nuclear Medicine. Oct2022, Vol. 63 Issue 10, p1-25. 25p.
Database: Engineering Source
Description
ISSN:01615505
DOI:10.2967/jnumed.122.264677